Royal London Asset Management
NVCR icon

Royal London Asset Management’s NovoCure NVCR Stock Holding History

Royal London Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-35,510
Closed -$4.12M – 669
2021
Q3 		$4.12M Hold
35,510
– – 0.02% 545
2021
Q2 		$7.88M Buy
35,510
+233
+0.7% +$45.3K 0.03% 382
2021
Q1 		$4.67M Buy
+35,277
New +$5.58M 0.02% 511

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal London Asset Management's NVCR Position: Q4 2021 in Review

Royal London Asset Management sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 35,510 shares — an estimated $4.12M sold.

Royal London Asset Management first reported a position in NVCR in Q1 2021 and held it in 3 quarters. The position peaked at $7.88M in Q2 2021. 311 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

  • Royal London Asset Management reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
  • Royal London Asset Management sold 35,510 NovoCure shares in Q4 2021, an estimated $4.12M.
  • Royal London Asset Management first reported a position in NovoCure in Q1 2021 and held it in 3 quarters.
  • Royal London Asset Management's NovoCure position peaked at $7.88M in Q2 2021.
  • 311 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on Royal London Asset Management's 13F filing for Q4 2021, filed 18 Jan 2022.